| Literature DB >> 23519222 |
Matthew B Cohen1, Jonathan T Stewart.
Abstract
Post-electroconvulsive therapy (ECT) delirium is commonly encountered in practice, occurring in up to 12% of treatments. Although often easily managed nonpharmacologically, more severe or persistent cases are generally treated with benzodiazepines or propofol. We describe a patient who failed to respond adequately to these medications but responded quite favorably to dexmedetomidine, a centrally acting α2 agonist. There is evidence that dexmedetomidine may have unique, "delirium-sparing" properties; this makes it an attractive option for this indication.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23519222 DOI: 10.1097/YCT.0b013e31827e56a7
Source DB: PubMed Journal: J ECT ISSN: 1095-0680 Impact factor: 3.635